Sell Thyrocare Technologies; target of Rs 307: Prabhudas Lilladher
Prabhudas Lilladher is bearish on Thyrocare Technologies has recommended sell rating on the stock with a target price of Rs 307 in its research report dated May 27, 2020.27-05-2020
27-05-2020
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
We are forwarding copy of Presentation on Audited Financial Results of our company for the quarter / whole year ended 31-03-2020. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised.25-05-2020
Thyrocare Technologies Ltd - 539871 - Results- Audited (Stand-Alone And Consolidated) Financial Results For The Financial Year Ended 31-03-2020
This is to inform you that our Board of Directors, at its meeting held today, approved the Audited Financial Results (Stand-alone & Consolidated) for the F.Y. ended 31-03-2020 and decided to not recommend any final dividend, considering the prevailing uncertain economic scenario. Board also approved granting of Stock Options to the eligible employees for 2019-20, subject to approval by Members. The Meeting commenced at 17.30 hours and concluded at 23.10 hours today. Pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulations, 2015, the following are attached. 1. Stand-alone and Consolidated Audited Financial Results for the quarter and the financial year ended 31-03-2020. 2. Auditors' Report on the Stand-alone Financial Results for the year ended 31-03-2020. 3. Auditors' Report on the Consolidated Financial Results for the year ended 31-03-2020. The statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results.23-05-2020
Thyrocare Technologies Ltd - 539871 - Outcome Of Board Meeting- 23-05-2020
This is to inform you that our Board of Directors, at its meeting held today, approved the Audited Financial Results (Stand-alone & Consolidated) for the F.Y. ended 31-03-2020 and decided to not recommend any final dividend, considering the prevailing uncertain economic scenario. Board also approved granting of Stock Options to the eligible employees for 2019-20, subject to approval by Members. The Meeting commenced at 17.30 hours and concluded at 23.10 hours today. Pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulations, 2015, the following are attached. 1. Stand-alone and Consolidated Audited Financial Results for the quarter and the financial year ended 31-03-2020. 2. Auditors' Report on the Stand-alone Financial Results for the year ended 31-03-2020. 3. Auditors' Report on the Consolidated Financial Results for the year ended 31-03-2020. The statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results.23-05-2020
Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter/Full Year Ended 31-03-2020, To Consider Recommending Final Dividend, If Any, To Consider Granting Employees Stock Options For Financial Year 2019-20
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/63 dated April 17, 2020, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, May 23, 2020, to inter alia, consider and approve Audited Stand-alone and Consolidated Financial Results of the Company for the quarter / full year ended March 31, 2020, to consider recommending final dividend, if any, for the financial year 2019-20, and to consider granting of stock options to the eligible employees for the financial year ended March 31, 2020. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.19-05-2020
Thyrocare Technologies Ltd - 539871 - Compliances- Compliance Certificate Under Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, For The Half Year Ended March 31, 2020
We are attaching herewith the Compliance Certificate dated 12-05-2020 issued by Mr. V. Suresh, Practising Company Secretary, pursuant to the Regulation 40 (9) of Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Half-year ended March 31, 2020. Please take the same on record.15-05-2020
Thyrocare Technologies Ltd - 539871 - Compliances- Compliance Certificate Under Regulation 7 (3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, For The Half Year Ended March 31, 2020.
As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the compliance certificate for the half year ended March 31, 2020. Please note that it has been digitally signed by undersigned and by the authorised representative of our Registrar, Link Intime India Private Limited in view of the current Lock Down situation. Please take the same on record.15-05-2020
Thyrocare Technologies Ltd - 539871 - Shareholding for the Period Ended March 31, 2020
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here14-05-2020
Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer14-05-2020